摘要
目的:探讨胃肠安丸对腹泻型肠易激综合征(diarrhea-predominant irritable bowel syndrome,IBS-D)大鼠止泻作用的药理机制。方法:运用高乳糖饲料喂饲与束缚应激相结合的方法复制IBS-D大鼠模型。雌性Wistar大鼠24只,随机分为空白组、模型组及胃肠安丸(60 mg.kg-1.d-1)组,通过比较各组大鼠体重增长率、观察腹泻潜伏期及腹泻指数,确定最佳用药周期。进一步将45只雌性Wistar大鼠分为空白组、模型组、胃肠安丸高、中、低剂量(80,60,40 mg.kg-1.d-1)组,光镜下观察各组结肠组织肥大细胞(MC)数目,硝酸酶还原法测定血清一氧化氮(NO)含量、运用荧光光度计检测血清5-羟色胺(5-HT)水平及放射免疫法测量结肠组织P物质(SP)含量。结果:用药后4 d胃肠安组与模型组体重增长率差值最大,且腹泻指数差别有统计学意义(P<0.05),因此确定最佳用药周期为4 d。与空白组比较,模型组血清NO及5-HT含量下降(P<0.01),SP含量升高(P<0.05),MC数目增多(P<0.01);与模型组比较,高、中剂量胃肠安丸可上调血清NO及5-HT含量(P<0.01),下调SP表达(P<0.05),并使肥大细胞数目减少(P<0.01)。结论:胃肠安丸的止泻作用机制与升高血清NO及5-HT含量有关,亦与抑制结肠组织SP表达及降低MC数目相关。
Objective:To investigate the influence of Weichang Anwan on the treatment of IBS-D in model rats.Method: Animal model of compound diarrhea was induced by a lactose enriched diet in the Wistar rat,combining with restraint stress.At first,the best cycle of taking medicine was tested.In order to decide the best cycle of taking medicine,24 female Wistar rats were randomly divided into normal control group,model group and 60 mg·kg-1·d-1 weichangan group.The rate of weight increase,the rate of diarrhea,the incuba...
出处
《中国中药杂志》
CAS
CSCD
北大核心
2009年第23期3073-3077,共5页
China Journal of Chinese Materia Medica
基金
天津市科技创新专项基金(06FZZDSH00405)
